Journal of Holistic and Scientific Studies

Article journey
Received
12/06/2026
Revised
13/07/2026
Accepted
20/07/2026
Published
27/07/2026

Traditional Medicinal-Plant Knowledge and Laboratory Validation Connecting Ethnobotany, Pharmacology and Community Healthcare

Marcello Ienca*
Department of Health Sciences and Technology, ETH Zurich (Swiss Federal Institut of Technology), Zurich, Switzerland

Abstract— **Traditional medicinal-plant knowledge continues to support primary healthcare, cultural identity, and therapeutic discovery, particularly in rural and underserved communities. This study synthesizes evidence linking ethnobotanical documentation with phytochemical analysis, pharmacological validation, safety assessment, quality standardisation, and community healthcare integration. Ethnobotanical approaches, including interviews, field walks, market surveys, voucher-specimen preparation, and quantitative indices, provide a systematic basis for identifying culturally important and therapeutically promising plant species. Laboratory validation then establishes plant identity, chemical composition, biological activity, mechanisms of action, toxicity, pharmacokinetics, and dose-response relationships through in-vitro, in-vivo, computational, and clinical methods. Emerging tools such as metabolomics, molecular docking, natural-product databases, network pharmacology, and artificial intelligence accelerate compound prioritisation and clarify multi-component, multi-target effects. However, adulteration, contamination, species misidentification, inconsistent extraction, poor bioavailability, herb-drug interactions, and insufficient clinical evidence continue to restrict safe implementation. Effective integration into community healthcare requires standardised formulations, professional supervision, pharmacovigilance, community education, sustainable harvesting, and collaboration among traditional healers, botanists, pharmacologists, pharmacists, clinicians, conservationists, and public-health specialists. The study also highlights methodological limitations and future priorities involving standardised protocols, clinical trials, multidisciplinary research, conservation, and personalised herbal medicine. Overall, connecting traditional knowledge with rigorous laboratory and clinical evidence expands accessible treatment options, strengthens patient safety, preserves medicinal biodiversity, and supports culturally appropriate, evidence-based healthcare.**

Keywords: Traditional medicinal plants; ethnobotany; pharmacological validation; community healthcare; phytochemical analysis

1. INTRODUCTION

Traditional knowledge of medicinal plants is a synthesis of experience and expertise on the identification, preparation, administration and therapeutic use of plant resources. This knowledge is typically acquired over time, because of community interaction with its surroundings, and is passed on orally, via community practices and traditions, traditional healers, and healthcare systems. Ethnobotanical studies in Southwestern Ethiopia have confirmed the rich knowledge of the indigenous population regarding the medicinal plants, the parts used, their preparation methods, and the specific therapeutic uses for various diseases (Agize et al., 2022). Other studies have been conducted in Yemen where local plants are still of significant use in the treatment of digestive, respiratory, dermatological and inflammatory disorders (Al-Fatimi, 2019). These traditions are not only historical in nature but also continue to be used as tools of health care especially in areas that lack formal medical services due to geographical and/or economic limitations.

Medicinal-plant knowledge also has cultural and ecological connotations and has locally developed methods of disease management. The various plant species are utilized by the indigenous communities of Pakistan for treating common ailments as well as chronic health issues, which further highlights the reliance on traditional medicine in rural areas of the country (Aziz et al., 2018). The Panay Bukidnon of the Philippines, like many other ethnic groups, also have documentation linking medicinal plant use to cultural beliefs and environmental resources, as well as intergenerational knowledge sharing (Cordero et al., 2022).

Ethnobotany offers a structured approach to analyzing the interactions between people, plants, cultural practices and health care. It helps to identify medicinal species commonly used, therapeutic indications, preparation methods, routes of administration and level of consensus among the traditional knowledge holders. In the community research conducted in Southwestern Ghana, medicinal trees are found to play a significant role in treating infectious diseases, pain, digestive disorders and other health issues affecting the communities (Asigbaase et al., 2024). Ethnobotanical knowledge remains pertinent in the Catalan linguistic area, even among communities with access to modern health care, in the treatment of gastrointestinal, metabolic and nutritional diseases (Cáceres et al., 2024).

Ethnobotanical studies can therefore be of importance to primary health care in providing an identification of affordable and culturally accepted therapeutic resources. In Turkey, Mersin, there has been the documentation of the extensive use of medicinal plants in households, and how local knowledge can be applied to selecting species for further studies for medicinal use (Emre et al., 2021). Similarly, the use of medicinal wild plants in the Shouf Biosphere Reserve in Lebanon is part of the local health care system, and it also draws an attention to the linkage between health, biodiversity, and sustainable utilization of resources (Hani et al., 2022).

Traditional use may be useful as a preliminary guide, but cannot stand alone for establishing clinical efficacy, safety, dosage, and/or mechanism of action. It is therefore crucial to validate the therapeutic claims in the laboratory to confirm the claim with phytochemical, microbiological, pharmacological and toxicological evidence. Experimental investigation can provide identification of bioactive compounds, dose-response relationships, antimicrobial or anti-inflammatory activity, and even the potential for toxicity or herb-drug interaction. If not, different plant species, different harvest conditions, different processing techniques or different dosages yield different and possibly adverse results.

For proper medicinal-plant research, cooperation should be encouraged among ethnobotanists and botanists, pharmacologists, toxicologists, clinicians, and public-health workers. Ethnobotany determines the culturally significant uses of parts as remedies, pharmacology provides a biological evaluation, and public health provides an evaluation of accessibility, acceptability, safety, and contribution to health-care delivery. To obtain trustworthy ethnopharmacological knowledge, field methods should be standardized, engagement ethical, knowledge of the plant reliable, informed consent must be given, and reports should be honest and transparent (Heinrich et al., 2018). Integration also helps to prevent the separation of laboratory results from the use context of the plants in the culture.

The objective of this study is to investigate the possibilities of linking traditional knowledge of medicinal plants with laboratory validation and community health care. It compiles the evidence covering ethnobotanical documentation, plant prioritization, phytochemical research, pharmacological research, safety assessment and healthcare integration. The study also aims to highlight methodological weaknesses, ethical issues and scope for interdisciplinary studies which help to bring traditional remedies into the safe, standardised and evidence-based healthcare arena.

2. Ethnobotanical Foundations of Traditional Medicinal-Plant Knowledge

2.1 Historical Development of Plant-Based Healing Systems

Healing systems derived from the observation of local flora and fauna, disease patterns, and therapeutic responses over a long period of time. Communities used medicinal plants as their main remedy for infections, injuries, digestive disorders, pains and chronic diseases before formal health care institutions were established. Historical healing practices in northern Ethiopia are still closely associated with the availability of species in local landscapes and with traditional use of plants (Kidane et al., 2018). In Morocco, medicinal and aromatic plants are still playing a role in the treatment of household diseases and in cultural medicine defined by the people (Lahyaoui et al., 2025).

2.2 Sources and Transmission of Indigenous and Local Knowledge

Indigenous medicinal knowledge is usually passed on by families, traditional healers, elders, herbal vendors, and community specialists, and is often spoken. Learning is frequently by observation, apprenticeship, and repetition in the collection of plants and the preparation of remedies. The knowledge of medicinal plants becomes part of the cultural identity, livelihood activities and the process of passing knowledge from one generation to the next among the Bulang of Yunnan (Zhou et al., 2023). Studies on childhood health care also reveal that knowledgeable persons are integral in maintaining remedies for common paediatric ailments (Ndhlovu et al., 2023). The movement of medicinal-plant knowledge from the community to the intergenerational transmission of knowledge, to formal ethnobotanical documentation is shown in Figure 1.



Figure 1. Transmission and Documentation of Traditional Medicinal-Plant Knowledge

2.3 Methods Used in Ethnobotanical Documentation

Semi-structured interviews, questionnaires, focus-group discussions, guided field walks, participant observation and plant-specimen collection are the most employed ethnobotanical documentation methods. The reliability and repeatability of field research improved with accurate taxonomic identification, voucher-specimen preparation, informed consent and transparent reporting (Weckerle et al., 2018). In addition, market surveys offer significant evidence about species availability, market demand, local names, medicinal plant therapeutic claims and medicinal plant trade patterns (Uzun & Koca, 2020). The ethnobotanical documentation involves the combination of complementary qualitative, botanical and quantitative approaches, which ensures that the knowledge of medicinal plants is documented in a way that is accurate and within the cultural context of traditional use, as described in Table 1.

Table 1. Core Components of Ethnobotanical Documentation

Documentation component	Purpose	Typical information collected	Strengths	Major limitations	Reference
Semi-structured interviews	Record individual knowledge and experiences	Local plant names, uses, preparation methods, dosage, and administration	Flexible and culturally responsive	Recall bias and interviewer influence	(Kidane et al., 2018)
Focus-group discussions	Examine shared and contrasting community	Consensus on therapeutic uses, cultural beliefs, and	Encourages discussion and collective validation	Dominant participants may influence	(Begum et al., 2022)

	knowledge	preparation practices		responses	
Guided field walks	Connect reported knowledge with plants in their natural habitats	Plant location, habitat, harvesting methods, and ecological availability	Supports direct species recognition	Seasonal availability may restrict observation	(Zhou et al., 2023)
Participant observation	Understand the practical application of remedies	Harvesting, processing, preparation, and administration	Captures contextual and practical knowledge	Time-consuming and dependent on community access	(Ndhlovu et al., 2023)
Herbal-market surveys	Document commercial medicinal-plant use	Traded species, prices, therapeutic claims, demand, and supply chains	Identifies frequently commercialised plants	Products may be misidentified or substituted	(Uzun & Koca, 2020)
Voucher-specimen preparation	Confirm and preserve botanical identity	Scientific name, collection site, date, collector, and accession number	Improves reproducibility and taxonomic accuracy	Requires herbarium and taxonomic expertise	(Weckerle et al., 2018)

2.4 Cultural Beliefs, Preparation Practices, and Routes of Administration

The cultural beliefs of the users concerning the causes of illness, the importance of spiritual health, food, environment and healing influence the use of medicinal plants. Remedies can be made as a decoction, infusion, powder, paste, juice or smoke and taken as an oral (internal), topical (external), nasal, or bathing remedy. These practices affect the chemical composition, dosage, therapeutic activity and safety. Studies of whole-plant extracts may result in synergistic or antagonistic effects, instead of from any single compound, due to the presence of multiple constituents in whole-plant extracts (Caesar & Cech, 2019).

2.5 Quantitative Ethnobotanical Indices for Identifying Priority Plants

The quantitative indices enable the researcher to select species of importance in the culture for laboratory study. Common measures include value, relative frequency of citation, fidelity level, informant consensus factor and cultural importance index. The findings of the quantitative assessment in District Malakand showed plants and high-consensus remedies that prioritised for phytochemical and pharmacological validation (Begum et al., 2022). This prioritisation helps to optimize the use of laboratory resources in natural product discovery by focusing on plants where there is strong community-based evidence (Atanasov et al., 2021).

2.6 Regional and Cultural Variations in Medicinal-Plant Use

The choice of medicinal plants varies from region to region, language to language, and religion to religion, and depends on the prevalence of the disease and the availability of the market. Different species may be used for similar diseases and disorders in communities from Ethiopia, Moroccan, Pakistan, Turkey, China and southern Africa, and they may be prepared differently. The differences highlight that knowledge of medicine is not one-size-fits-all but is not static. Comparative ethnobotanical research is thus required to differentiate broadly shared patterns of therapeutic uses from those of a more local nature (Agize et al., 2022).

3. Selection and Prioritisation of Medicinal Plants for Laboratory Validation

3.1 Ethnobotanical Criteria for Selecting Candidate Plants

The choice of medicinal plants to be investigated in the laboratory should start with clear ethnobotanical data. Commonly used species, those with high level of community agreement, and plants used for serious or recurring diseases are generally appropriate, as are plants with unique methods of preparation. This prioritisation reduces the huge number of varieties of plants to a group that can be studied in detail. The bioprospecting of traditional uses is now increasingly acknowledged as an effective way to start discovering biologically active natural products (Lautié et al., 2020). The ongoing success of natural products in approved medicines further reinforces the ongoing study of traditionally important species (Newman & Cragg, 2020).

3.2 Use-Value, Informant Consensus, and Fidelity-Level Approaches

The quantitative ethnobotanical indices support the selection process by calculating the cultural values and consensus among the knowledge holders. Use-value reflects the relative importance of a plant, depending on the number of reported uses, while the informant consensus factor reflects how much consensus there is on the remedies used for specific disease groups. The proportion of informants associating a plant with a therapeutic purpose is called fidelity level. High scores for these indices on plants provide better support for pharmacologic research. Utilizing curated databases of phytochemicals and therapeutics can also help identify if the selected species contain previously reported compounds or biological activities in combination with these measures (Mohanraj et al., 2018). The candidate medicinal plants can be ranked using the criteria mentioned in Table 2, which is a combination of ethnobotanical importance, biological plausibility, chemical novelty, safety and conservation status.

Table 2. Criteria for Prioritising Medicinal Plants for Laboratory Validation

Prioritisation criterion	Meaning or measurement	Importance for laboratory validation	Example of interpretation	Reference
Use value	Frequency and diversity of reported uses	Identifies plants with high cultural importance	A high value indicates repeated use for several conditions	(Begum et al., 2022)
Informant consensus factor	Agreement among informants regarding plants used for a disease	Highlights remedies with strong community	High consensus may indicate reproducible therapeutic	(Balekundri & Mannur, 2020)

	category	agreement	experience	
Fidelity level	Proportion of informants reporting one plant for a specific condition	Identifies plants strongly associated with a particular indication	A high fidelity level supports disease-specific testing	(Begum et al., 2022)
Frequency of citation	Number of respondents mentioning a species	Identifies widely recognised medicinal plants	Frequently cited plants may be prioritised for initial screening	(Lautié et al., 2020)
Existing phytochemical evidence	Presence of known or potentially active compounds	Supports hypothesis development and assay selection	Database records may reveal relevant metabolites or targets	(Mohanraj et al., 2018)
Chemical novelty	Probability of identifying structurally distinct compounds	Increases drug-discovery potential	Unexplored species may provide new molecular scaffolds	(Newman & Cragg, 2020)
Sustainability and availability	Population status and feasibility of harvesting	Prevents research-driven depletion of vulnerable species	Rare or threatened plants may require cultivation alternatives	(Thomford et al., 2018)

3.3 Plant Identification, Authentication, and Voucher-Specimen Preparation

Correct botanical identification is critical taxonomic misidentification result in invalid lab results and poses a safety risk. The plants being collected should be harvested with the reproductive organs where possible and identified by trained botanists. Voucher specimens should be lodged in recognised herbaria under an accession number, locality, local name, date and collector data. Precise authentication also allows for future researchers to replicate the study and compare results between regions. The process assisted by digital databases and computational tools, which enable verified species to be correlated with known phytochemical and pharmacological information (Grazina et al., 2020).

3.4 Collection, Processing, Storage, and Extraction Methods

Collection and processing methods have a strong impact on the chemical composition of plant material. The part of the plant, developmental stage, harvesting time, drying condition, storage time and extraction solvent should be recorded in the research. For assessing the community remedies, the traditional preparations should be reproduced, and other solvents can be used to isolate compounds with different polarities. Targeted extraction, through innovative omics-based strategies, can help to lower the number of known compounds to be isolated repeatedly (Wolfender et al., 2019). Some tools, like SIRIUS 4, can help to interpret tandem mass spectrometry data quickly, thereby speeding up the process of metabolite identification (Dührkop et al., 2019).

3.5 Influence of Geographical, Seasonal, and Environmental Factors

The phytochemical composition varies depending on soil, elevation, rainfall, temperature, season and ecological stress. Thus, different samples can be expected to yield different pharmacologic effects. The need for standardised sampling and comparative chemical profiling to assess the efficacy that may be linked to a specific ecological context in traditional use. Complex metabolite patterns compared between samples and location-specific chemical variations identified, using molecular-networking platforms (Ernst et al., 2019).

3.6 Challenges in Translating Traditional Claims into Testable Hypotheses

Traditional claims are usually general, culturally specific or symptom-based and do not necessarily align with biomedical diagnosis. Researchers need to translate such statements into measurable outcomes, without stripping away the cultural context. The advantage of network pharmacology is that most of the herbal medicines are polypharmacological drugs that usually interact with several compounds and molecular targets (Zhang et al., 2019). This systems-level approach provides a better understanding of complex therapeutic effects and enables the exploration of causal biological pathways rather than symptoms (Nogales et al., 2022). However, proper hypothesis, controls, disease models, and ethnobotanical knowledge and integration with modern pharmacology have to be done with care to achieve successful translation (Thomford et al., 2018). In Figure 2, the sequential pathway shows how traditional therapeutic claims transformed into research questions that can be tested experimentally.



Figure 2. Ethnobotany-Guided Selection and Laboratory Validation Pathway

4. Phytochemical and Pharmacological Validation

4.1 Preliminary Phytochemical Screening

Preliminary phytochemical screening is the first laboratory evaluation of extracts from medicinal plants which involves the identification of major classes of secondary metabolites such as alkaloids, flavonoids, tannins, terpenoids, saponins, phenolics and glycosides. These compounds have a wide range of biological activities such as antioxidant, antimicrobial, anti-inflammatory, antidiabetic, and anticancer effects. Specialised natural-product databases can assist researchers to compare the compounds detected to those already reported in the literature for their biological activity and structure (Sorokina & Steinbeck, 2020). In addition, the COCONUT database also contains openly accessible chemical information for natural products obtained from a wide variety of biological sources which helps in compound identification (Sorokina et al., 2021).

4.2 Isolation and Characterisation of Bioactive Compounds

After screening, constituents are separated and characterised by chromatographic and spectroscopic techniques to locate the active constituents. These are often the techniques of high-performance liquid chromatography, gas chromatography, liquid chromatography-mass spectrometry, nuclear magnetic resonance spectroscopy and infrared spectroscopy. To enhance dereplication, avoid repeated isolation of known compounds and improve the accuracy of structural data, updated resources like COCONUT 2.0 provide better-curated structural data (Chandrasekhar et al., 2025). Traditional-medicine databases like ETCM also link herbs and herb ingredients to chemical constituents, therapeutic functions and potential molecular targets (Xu et al., 2019).

4.3 In-Vitro Pharmacological Assays

In-vitro assays are used to test biological activity in a lab setting. Extracts can be screened for antimicrobial, antioxidant, enzyme inhibitory, anti-inflammatory, cytotoxic or glucose regulating properties depending on the traditional claims. Medicinal plants utilized in Islamic and Arabic medical care systems have revealed anticancer properties in cell-based investigations, but additional investigation is required for these plants before they can be considered for use as medicines in cancer treatment (Ahmad et al., 2017). In the same way, some phytochemicals derived from plants have exhibited antidiabetic activity by inhibiting the carbohydrate digesting enzymes, increasing insulin sensitivity and protecting the pancreatic cells (Alam et al., 2022). Phytochemical and pharmacological validation done through different complementary analytical and biological approaches, the aims of which and the products thereof are outlined in Table 3.

Table 3. Major Approaches Used in Phytochemical and Pharmacological Validation

Validation approach	Principal purpose	Typical techniques or models	Expected output	Reference
Preliminary phytochemical screening	Identify broad metabolite classes	Qualitative tests for alkaloids, flavonoids, tannins, saponins, and terpenoids	Initial chemical profile of the extract	(Ashokkumar et al., 2020)
Chromatographic separation	Separate compounds within complex extracts	HPLC, GC, LC-MS, TLC, and column chromatography	Fractions and isolated constituents	(Chandrasekhar et al., 2025)
Structural characterisation	Determine compound identity and structure	NMR, mass spectrometry, infrared spectroscopy, and database	Confirmed or predicted chemical structures	(Sorokina & Steinbeck, 2020)

		matching		
In-vitro bioassays	Test activity under controlled conditions	Enzyme inhibition, microbial cultures, cell lines, and antioxidant assays	Potency, selectivity, and concentration-response evidence	(Alam et al., 2022)
In-vivo disease models	Evaluate efficacy and safety in whole organisms	Diabetic, inflammatory, infectious, tumour, or toxicity models	Physiological efficacy, dose-response, and organ-level effects	(Ahmad et al., 2017)
Molecular-target analysis	Explain mechanisms of action	Receptor assays, pathway analysis, gene-expression studies	Identification of biological targets and pathways	(Mao et al., 2019)
Network pharmacology	Analyse multi-compound and multi-target effects	Compound-target-disease networks and pathway enrichment	Systems-level mechanism of herbal remedies	(Fang et al., 2021)
Natural-product databases	Support dereplication and evidence retrieval	COCONUT, ETCM, HERB, and other curated databases	Known compounds, targets, activities, and literature links	(Xu et al., 2019)

4.4 In-Vivo Efficacy Studies and Disease Models

In-vivo experiments are experiments that test the persistence of laboratory activity in a living organism. Animal models are frequently utilized to assess efficacy, toxicity, dosage and physiological response before clinical testing. Cardamom is also studied for its antioxidant, antimicrobial, anti-inflammatory, metabolic and gastroprotective activities, highlighting the need for a combination of traditional use and experimental studies (Ashokkumar et al., 2020). Reliable findings only come from appropriate controls, validated disease models and ethical procedures.

4.5 Mechanisms of Action and Molecular Targets

Mechanistic studies elucidate the effects of plant compounds on receptors, enzymes, signaling pathways, gene expression, and inflammatory mediators. The many compounds in ginger exert their activity through antioxidant, anti-inflammatory, metabolic and cellular signalling pathways. This analysis done using databases like HERB that connect traditional medicines with ingredients, targets, diseases, and experimentally validated evidence (Fang et al., 2021).

4.6 Pharmacokinetics, Bioavailability, and Dose–Response Relationships

Pharmacokinetic evaluation includes absorption, distribution, metabolism and elimination. Many phytochemicals demonstrate good in vitro activity but have low therapeutic activity, due to low solubility, rapid metabolism or low systemic availability. It is therefore important to conduct dose-response studies to find safe and effective dose ranges, and to establish a separation of therapeutic effects and toxic effects (Cordero et al., 2022).

4.7 Application of Metabolomics, Molecular Docking, and Network Pharmacology

Molecular docking used to predict the interactions between plant compounds and biological targets, and metabolomics used to profile complex extracts. Multi-compound/multi-target relationships are also explored by network pharmacology. Combined with curated databases, these tools enhance compound prioritisation, mechanistic interpretation and scientific validation of traditional medicinal-plant treatments. Figure 3 is an integrated framework that connects various modes of chemical characterisation, biological testing, computational prediction and pharmacokinetic evaluation.



Figure 3. Integrated Phytochemical and Pharmacological Validation Framework

5. Safety, Toxicology, and Quality Standardisation

5.1 Traditional Perceptions of Safety versus Scientific Evidence

The medicinal plants are generally regarded as safe due to their naturalness and generations-long use. But with the old familiarity comes no guarantee of toxicity, reaction or wrong dosing. Plant remedies contain high concentrations of bioactive ingredients that are known to have a variety of effects, depending on the type of plant, how they are made, how high the concentration is and how long they are used. The study on medicinal plants of Mauritius has shown that there is a lot of ethnopharmacological use of medicinal plants, and therefore systematic toxicological and clinical evaluation is required before their use in therapy (Suroowan et al., 2019). Although many compounds including anthocyanins and curcumin have already been studied, even a careful evaluation of the effective doses, metabolism, adverse effects, and long-term safety is needed (Salehi et al., 2020; Sharifi-Rad et al., 2020).

5.2 Acute, Subacute, Chronic, and Reproductive Toxicity Testing

Toxicological testing is done in the following sequence acute, subacute, chronic, genotoxic, reproductive, and developmental. Acute studies assess immediate toxicity and approximate lethal or maximum tolerated doses, while repeated-dose studies assess cumulative effects on organs and blood parameters, metabolism and behavior. Reproductive studies are especially critical for remedies in use for pregnant women, lactating women, and children. Safe levels of exposure should be determined through testing with standardised extracts, with a variety of dose levels, controls and with histopathological examination.

5.3 Herb-Drug Interactions and Contraindications

Herbal products affect the way conventional medicines are absorbed, metabolized, transported or eliminated from your body. The interactions may be via cytochrome P450 enzymes, drug transporters, additive pharmacological effects, or antagonistic effects. However, causality assessment is still challenging as patients can take multiple remedies without notifying health care providers (Awortwe et al., 2018). Particularly problematic are clinically significant interactions, such as those that have the potential to diminish the effectiveness of chemotherapy, or to heighten the toxicity of the herbal products in the context of cancer treatment (Fasinu & Rapp, 2019). Therefore, clinical efficacy, adverse events and contraindications should be evaluated as a whole and not individually (Izzo et al., 2016).

5.4 Contamination, Adulteration, and Misidentification Risks

Herbal products contain microorganisms, pesticides, heavy metals, pharmaceuticals or other plant material. Misidentification and substitution also lead to consumers being exposed to species that are not effective and even toxic ones. There has been a high rate of adulteration of commercial herbal products, even though the accuracy of the labels cannot always be assumed (Ichim, 2019).

5.5 Standardisation of Extracts and Herbal Formulations

Standardisation guarantees uniformity of the identity, chemical composition, potency, purity and dosage of the plant. It must involve validated extraction procedures, chemical fingerprinting, marker-compound analysis as well as authenticated raw materials and stability testing. The quality control is an amalgam of botanical, physicochemical, chromatographic, microbiological and molecular approaches (Balekundri & Mannur, 2020). As detailed in Table 4, coordinated botanical, chemical, toxicological, clinical and regulatory controls are needed to ensure the safe incorporation of medicinal-plant products into healthcare.

Table 4. Safety, Quality, and Healthcare-Integration Requirements

Requirement	Main purpose	Key assessment or action	Relevance to community healthcare	Reference
Botanical authentication	Confirm the correct medicinal species	Morphology, microscopy, DNA barcoding, and voucher specimens	Prevents substitution and use of toxic species	(Raclariu et al., 2018)
Chemical standardisation	Ensure consistent composition and potency	Chemical fingerprints, marker compounds, purity, and stability	Supports consistent dosing and therapeutic outcomes	(Balekundri & Mannur, 2020)
Contaminant testing	Detect unsafe foreign substances	Heavy metals, pesticides, microorganisms, and pharmaceutical	Reduces preventable toxicity	(Upton et al., 2020)

		adulterants		
Toxicological assessment	Establishes safe exposure limits	Acute, subacute, chronic, reproductive, and genotoxicity testing	Protects vulnerable users and long-term consumers	(Sharifi-Rad et al., 2020)
Herb–drug interaction assessment	Identify clinically significant interactions	Enzyme inhibition, transporter effects, clinical monitoring	Essential for patients receiving conventional medicines	(Awortwe et al., 2018)
Product authentication	Confirm fidelity of commercial products	DNA barcoding, metabarcoding, and chemical analysis	Improves label accuracy and consumer confidence	(Seethapathy et al., 2019)
Professional guidance	Promote safe and appropriate use	Counselling by healers, pharmacists, and clinicians	Reduces unsafe self-medication	(Samuels et al., 2017)
Pharmacovigilance	Monitor adverse reactions after implementation	Reporting systems, clinical follow-up, and product traceability	Supports continuous safety assessment	(Grazina et al., 2020)

5.6 Good Agricultural, Collection, Manufacturing, and Laboratory Practices

Good cultivation and collection practices are used to control cultivation, harvesting, drying, transport and storage. Good manufacturing and laboratory practices are used to ensure reproducibility and control contamination. Better training, documentation, research infrastructure and collaboration between healers, regulators and scientists are also needed in traditional-medicine systems (Gakuya et al., 2020).

5.7 Regulatory Requirements for Medicinal-Plant Products

Regulatory requirements should include evidence of identity, quality, safety, efficacy, accurate labelling, pharmacovigilance and traceability. Requirements should be stringent enough to ensure consumer protection, while at the same time being proportionate to the intended use to facilitate the responsible incorporation of validated medicinal-plant products into healthcare systems.

6. Integration into Community Healthcare Systems

6.1 Current Role of Medicinal Plants in Primary and Rural Healthcare

Medicinal plants continue to play a significant role in primary healthcare, especially in rural and less developed areas where medical facilities and trained health professionals and medicines may be scarce. They are still used because they are readily available, culturally understood and trusted by the community. But plant resources that underpin much of traditional medical care are becoming endangered due to biodiversity loss and conservation is needed to ensure future access to medicinal species (Díaz et al., 2019). More general assessments of diversity for food and agriculture also highlight the significance of maintaining plant biodiversity for health and nutrition, and for the livelihoods of rural communities (Bélanger & Pilling, 2019).

6.2 Evidence-Based Integration with Conventional Medicine

The acceptance of traditional medicine in conventional medicine depends on reliable information about the identity of the plant, therapeutic effectiveness, dosage, toxicity, contraindications and interactions. Herbal remedies should be used in addition to required clinical treatment. However, when patients with serious diseases, such as breast cancer, use herbs without monitoring, they may have unrealistic expectations, delayed treatment, or clinically significant interactions (Samuels et al., 2017). Effective integration, based on evidence, thus involves dialogue between patients, traditional practitioners, pharmacists and physicians.

6.3 Accessibility, Affordability, and Cultural Acceptability

Often, medicinal plants are more readily available and less expensive than manufactured medicines, particularly if one's household can grow or gather the plants locally. They also may be more acceptable within their cultural context and enhance adherence to treatment due to their consistency with the community's beliefs and familiar healing practices. However, it must go hand in hand with sustainable harvesting and biodiversity protection. The international biodiversity frameworks promote conservation and sustainable use of biological resources and the recognition of the role they play in human well-being (Framework, 2022).

6.4 Role of Traditional Healers, Pharmacists, and Healthcare Professionals

Traditional healers can record preparation methods, identify culturally significant remedies and know of locally understood categories of illness. Drug dosage, drug interactions, contraindications and quality of products evaluated by pharmacists and healthcare professionals. Collaborative health care models should consider Indigenous peoples and local communities knowledge and agency, and enable equitable participation and benefit-sharing (Reyes-García et al., 2022).

6.5 Community Education and Responsible Self-Medication

Community education to explain that natural products are not necessarily safe. Help the user identify, dose, prepare, treatment time and any adverse reactions and what to do when they need professional care. Authentication is especially crucial as DNA based studies have revealed substitution and contamination of marketed herbal products (Grazina et al., 2020). DNA barcoding and metabarcoding can be used to complement species verification but have technical limitations that should also be used in conjunction with chemical and botanical methods (Raclariu et al., 2018).

6.6 Clinical Validation and Implementation of Validated Remedies

Before routine implementation, the validated remedies should be clinically tested in stages. Safety, efficacy, dose-response relationship and comparison with existing treatment evaluated through clinical studies. Thus, questions related to product identity and fidelity of commercial Ayurvedic products point to the need for laboratory authentication and regulation before clinical use (Seethapathy et al., 2019). A combination of macroscopic, microscopic, chemical, chromatographic and molecular techniques adds more solid evidence to confirm the identity and quality of the ingredients (Upton et al., 2020).

6.7 Opportunities for Improving Healthcare Outcomes in Underserved Populations

Medicinal plants validated by scientific methods help work to increase options for affordable treatment, enhance preventive health care, and provide for solutions appropriate in the local context. Nurturing the medicinal biodiversity through community-based cultivation, sustainable harvesting practices, practitioner training, pharmacovigilance, and referral networks can enhance safety. Integrated programmes need therefore to be linked with traditional knowledge, conservation, laboratory and clinical practice, to achieve equity in health care. The following section suggests a community-based model (Figure 4) for integration of scientifically established medicinal plants in primary health care.



Figure 4. Model for Integrating Validated Medicinal Plants into Community Healthcare

7. Conservation and Future Research Directions

7.1 Sustainable Harvesting and Medicinal-Plant Conservation

The increasing demand for herbal products may lead to overharvesting and destruction of habitats and rare medicinal species. Sustainable approaches should consist of cultivation, controlled collection, seasonal harvesting, habitat restoration, seed banking and community-based conservation. It is also vital to preserve the biodiversity of medicinal plants to conserve traditional knowledge systems and future pharmacological resources (Vandebroek et al., 2020).

7.2 Methodological Improvement in Ethnopharmacological Research

Many of the current studies on ethnopharmacology are of limited numbers of patients, plant misidentification, inadequate dosage data, lack of controls, and poor reporting of medicine preparation. In the future, the use of standardised procedures for botanical authentication, extraction, phytochemical analysis, toxicity testing, pharmacological assays and data reporting will increase reliability and comparability.

7.3 Clinical Validation and Multidisciplinary Collaboration

Laboratory results showing promise should be followed with pharmacokinetic, dose optimisation, safety and well-designed clinical trials. The involvement of different actors such as traditional healers, ethnobotanists, botanists, pharmacologists, clinicians, conservationists and public-health specialists can help improve the scientific validity and facilitate the practical use of validated remedies (Jefferson, 2025).

7.4 Emerging Technologies and Future Opportunities

Bioactive-compound identification can be accelerated by artificial intelligence, metabolomics, genomics, proteomics, molecular docking, and network pharmacology, which can also help to elucidate multi-target mechanisms. These technologies can also facilitate personalised herbal medicine through the connection between phytochemical profile and individual biological characteristics and disease pathways.

8. Conclusion

The traditional knowledge of medicinal plants is an important intersection of tradition, biodiversity and community healthcare. Ethnobotanical documentation is of great importance to obtain information on the selection of plants, preparation methods, therapeutic applications, and knowledge-sharing practices. But traditional use is not enough to prove efficacy, safety, dosage or clinical suitability. Thus, laboratory validation by phytochemical screening, compound characterisation, pharmacological assays, toxicity studies, and mechanistic investigation is required to translate traditional claims to scientifically validated health care interventions. The first step of reliable validation is proper identification of plants, standardised collection, proper extraction and reproducible experimental methods. These advanced strategies, such as metabolomics, molecular docking, artificial intelligence, and network pharmacology, can enhance compound prioritization and unravel multi-target mechanisms. However, encouraging results in the laboratory still need to be accompanied by a pharmacokinetic study, dose optimisation and a properly designed clinical trial. Quality control, quality authentication and pharmacovigilance are also critical as adulteration, contamination, misidentification and herb-drug interactions can impact patient safety. Community health care integration should honour and uphold cultural practices and encourage appropriate use, professional monitoring and responsible self-medication. The safe implementation relies on collaboration among traditional healers, pharmacists, clinicians, researchers and public-health professionals. The principles of protection of the Indigenous intellectual property, prior informed consent, equitable benefit sharing and sustainable harvesting should continue to be the focus in research and commercial development. The relationship between ethnobotany and pharmacology/community health can ultimately lead to increase in cheap therapeutic options, and the conservation of medicinal biodiversity and knowledge.

References

1. Agize, M., Asfaw, Z., Nemomissa, S., & Gebre, T. (2022). Ethnobotany of traditional medicinal plants and associated indigenous knowledge in Dawuro Zone of Southwestern Ethiopia. Journal of Ethnobiology and Ethnomedicine, 18(1), 48. https://doi.org/10.1186/s13002-022-00546-4
2. Ahmad, R., Ahmad, N., Naqvi, A. A., Shehzad, A., & Al-Ghamdi, M. S. (2017). Role of traditional Islamic and Arabic plants in cancer therapy. Journal of Traditional and Complementary Medicine, 7(2), 195–204.
3. Alam, S., Sarker, M. M. R., Sultana, T. N., Chowdhury, M. N. R., Rashid, M. A., Chaity, N. I., Zhao, C., Xiao, J., Hafez, E. E., & Khan, S. A. (2022). Antidiabetic phytochemicals from medicinal plants: Prospective candidates for new drug discovery and development. Frontiers in Endocrinology, 13, 800714.
4. Al-Fatimi, M. (2019). Ethnobotanical survey of medicinal plants in central Abyan governorate, Yemen. Journal of Ethnopharmacology, 241, 111973.
5. Ashokkumar, K., Murugan, M., Dhanya, M. K., & Warkentin, T. D. (2020). Botany, traditional uses, phytochemistry and biological activities of cardamom [Elettaria cardamomum (L.) Maton]–A critical review. Journal of Ethnopharmacology, 246, 112244.
6. Asigbaase, M., Adusu, D., Musah, A. A., Anaba, L., Nsor, C. A., Abugre, S., & Derkyi, M. (2024). Ethnobotanical and ethnopharmacological survey of medicinal tree species used in the treatment of diseases by forest-fringe communities of Southwestern Ghana. Heliyon, 10(1). https://www.cell.com/heliyon/fulltext/S2405-8440(23)10853-X?uuid=uuid%3Ab49177f7-d13a-470d-90d5-06cfb1c3cf23
7. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). International natural product sciences taskforce. Nat. Rev. Drug Discov, 20(3), 200–216.
8. Awortwe, C., Makiwane, M., Reuter, H., Muller, C., Louw, J., & Rosenkranz, B. (2018). Critical evaluation of causality assessment of herb–drug interactions in patients. British Journal of Clinical Pharmacology, 84(4), 679–693. https://doi.org/10.1111/bcp.13490
9. Aziz, M. A., Adnan, M., Khan, A. H., Shahat, A. A., Al-Said, M. S., & Ullah, R. (2018). Traditional uses of medicinal plants practiced by the indigenous communities at Mohmand Agency, FATA, Pakistan. Journal of Ethnobiology and Ethnomedicine, 14(1), 2. https://doi.org/10.1186/s13002-017-0204-5
10. Balekundri, A., & Mannur, V. (2020). Quality control of the traditional herbs and herbal products: A review. Future Journal of Pharmaceutical Sciences, 6(1), 67. https://doi.org/10.1186/s43094-020-00091-5
11. Begum, H. A., Hamayun, M., Khan, A., Yaseem, T., Bussmann, R. W., & Murad, W. (2022). Quantitative ethnobotanical appraisal of medicinal plants used by indigenous communities of District Malakand, Pakistan. Ethnobotany Research and Applications, 24, 1–14.
12. Bélanger, J., & Pilling, D. (2019). The state of the world's biodiversity for food and agriculture. FAO; https://openknowledge.fao.org/items/b355c300-72ed-4a63-be07-8295c80ec7f1
13. Cáceres, F., Vallès, J., & Gras, A. (2024). Exploring ethnobotany in the Catalan linguistic area: Traditional plant-based knowledge for addressing gastrointestinal, metabolic, and nutritional disorders. Plants, 13(17), 2453.
14. Caesar, L. K., & Cech, N. B. (2019). Synergy and antagonism in natural product extracts: When 1+ 1 does not equal 2. Natural Product Reports, 36(6), 869–888.
15. Chandrasekhar, V., Rajan, K., Kanakam, S. R. S., Sharma, N., Weißenborn, V., Schaub, J., & Steinbeck, C. (2025). COCONUT 2.0: A comprehensive overhaul and curation of the collection of open natural products database. Nucleic Acids Research, 53(D1), D634–D643.
16. Cordero, C. S., Meve, U., & Alejandro, G. J. D. (2022). Ethnobotanical documentation of medicinal plants used by the indigenous panay bukidnon in lambunao, iloilo, Philippines. Frontiers in Pharmacology, 12,

790567.
17. Díaz, S., Settele, J., Brondízio, E. S., Ngo, H. T., Agard, J., Arneth, A., Balvanera, P., Brauman, K. A., Butchart, S. H. M., Chan, K. M. A., Garibaldi, L. A., Ichii, K., Liu, J., Subramanian, S. M., Midgley, G. F., Miloslavich, P., Molnár, Z., Obura, D., Pfaff, A., … Zayas, C. N. (2019). Pervasive human-driven decline of life on Earth points to the need for transformative change. Science, 366(6471), eaax3100. https://doi.org/10.1126/science.aax3100
18. Dührkop, K., Fleischauer, M., Ludwig, M., Aksenov, A. A., Melnik, A. V., Meusel, M., Dorrestein, P. C., Rousu, J., & Böcker, S. (2019). SIRIUS 4: A rapid tool for turning tandem mass spectra into metabolite structure information. Nature Methods, 16(4), 299–302.
19. Emre, G., Dogan, A., Haznedaroglu, M. Z., Senkardes, I., Ulger, M., Satiroglu, A., Can Emmez, B., & Tugay, O. (2021). An ethnobotanical study of medicinal plants in Mersin (Turkey). Frontiers in Pharmacology, 12, 664500.
20. Ernst, M., Kang, K. B., Caraballo-Rodríguez, A. M., Nothias, L.-F., Wandy, J., Chen, C., Wang, M., Rogers, S., Medema, M. H., & Dorrestein, P. C. (2019). MolNetEnhancer: Enhanced molecular networks by integrating metabolome mining and annotation tools. Metabolites, 9(7), 144.
21. Fang, S., Dong, L., Liu, L., Guo, J., Zhao, L., Zhang, J., Bu, D., Liu, X., Huo, P., & Cao, W. (2021). HERB: A high-throughput experiment-and reference-guided database of traditional Chinese medicine. Nucleic Acids Research, 49(D1), D1197–D1206.
22. Fasinu, P. S., & Rapp, G. K. (2019). Herbal interaction with chemotherapeutic drugs—A focus on clinically significant findings. Frontiers in Oncology, 9, 1356.
23. Framework, B. (2022). Decision adopted by the Conference of the Parties to the Convention on Biological Diversity. Conference of the Parties to the Convention on Biological Diversity (15th: 2021-2022: Kunming, China; Montréal, Canada and Nairobi)(DHLAUTH) 939522. https://www.informea.org/sites/default/files/decisions/cbd/52000000cbd0050000001741/cop-15-dec-08-en.pdf
24. Gakuya, D. W., Okumu, M. O., Kiama, S. G., Mbaria, J. M., Gathumbi, P. K., Mathiu, P. M., & Nguta, J. M. (2020). Traditional medicine in Kenya: Past and current status, challenges, and the way forward. Scientific African, 8, e00360.
25. Grazina, L., Amaral, J. S., & Mafra, I. (2020). Botanical origin authentication of dietary supplements by DNA-based approaches. Comprehensive Reviews in Food Science and Food Safety, 19(3), 1080–1109. https://doi.org/10.1111/1541-4337.12551
26. Hani, N., Baydoun, S., Nasser, H., Ulian, T., & Arnold-Apostolides, N. (2022). Ethnobotanical survey of medicinal wild plants in the Shouf Biosphere Reserve, Lebanon. Journal of Ethnobiology and Ethnomedicine, 18(1), 73. https://doi.org/10.1186/s13002-022-00568-y
27. Heinrich, M., Lardos, A., Leonti, M., Weckerle, C., Willcox, M., Applequist, W., Ladio, A., Long, C. L., Mukherjee, P., & Stafford, G. (2018). Best practice in research: Consensus statement on ethnopharmacological field studies–ConSEFS. Journal of Ethnopharmacology, 211, 329–339.
28. Ichim, M. C. (2019). The DNA-based authentication of commercial herbal products reveals their globally widespread adulteration. Frontiers in Pharmacology, 10, 1227.
29. Izzo, A. A., Hoon-Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016). A Critical Approach to Evaluating Clinical Efficacy, Adverse Events and Drug Interactions of Herbal Remedies. Phytotherapy Research, 30(5), 691–700. https://doi.org/10.1002/ptr.5591
30. Jefferson, D. J. (2025). The World Intellectual Property Organization Treaty on genetic resources and traditional knowledge: Implications for plant science. PLANTS, PEOPLE, PLANET, 7(4), 901–905. https://doi.org/10.1002/ppp3.10615
31. Kidane, L., Gebremedhin, G., & Beyene, T. (2018). Ethnobotanical study of medicinal plants in Ganta Afeshum District, Eastern Zone of Tigray, Northern Ethiopia. Journal of Ethnobiology and Ethnomedicine, 14(1), 64. https://doi.org/10.1186/s13002-018-0266-z
32. Lahyaoui, M., Dakka, N., El Menyiy, N., Sobeh, M., Razi, P., Goh, K. W., Al-Worafi, Y. M., Farrukh, M. J., & Bouyahya, A. (2025). Ethnobotanical survey of medicinal and aromatic plants used by the population of Settat Province, Morocco. Heliyon, 11(3). https://www.cell.com/heliyon/fulltext/S2405-8440(25)00703-0
33. Lautié, E., Russo, O., Ducrot, P., & Boutin, J. A. (2020). Unraveling plant natural chemical diversity for drug discovery purposes. Frontiers in Pharmacology, 11, 397.
34. Mao, Q.-Q., Xu, X.-Y., Cao, S.-Y., Gan, R.-Y., Corke, H., Beta, T., & Li, H.-B. (2019). Bioactive compounds and bioactivities of ginger (Zingiber officinale Roscoe). Foods, 8(6), 185.
35. Mohanraj, K., Karthikeyan, B. S., Vivek-Ananth, R. P., Chand, R. B., Aparna, S. R., Mangalapandi, P., & Samal, A. (2018). IMPPAT: A curated database of I ndian M edicinal P lants, P hytochemistry A nd T herapeutics. Scientific Reports, 8(1), 4329.

36. Ndhlovu, P. T., Asong, J. A., Omotayo, A. O., Otang-Mbeng, W., & Aremu, A. O. (2023). Ethnobotanical survey of medicinal plants used by indigenous knowledge holders to manage healthcare needs in children. PloS One, 18(3), e0282113.
37. Newman, D. J., & Cragg, G. M. (2020). Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285
38. Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. (2022). Network pharmacology: Curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences, 43(2), 136–150.
39. Raclariu, A. C., Heinrich, M., Ichim, M. C., & De Boer, H. (2018). Benefits and Limitations of DNA Barcoding and Metabarcoding in Herbal Product Authentication. Phytochemical Analysis, 29(2), 123–128. https://doi.org/10.1002/pca.2732
40. Reyes-García, V., Fernández-Llamazares, Á., Aumeeruddy-Thomas, Y., Benyei, P., Bussmann, R. W., Diamond, S. K., García-del-Amo, D., Guadilla-Sáez, S., Hanazaki, N., Kosoy, N., Lavides, M., Luz, A. C., McElwee, P., Meretsky, V. J., Newberry, T., Molnár, Z., Ruiz-Mallén, I., Salpeteur, M., Wyndham, F. S., … Brondizio, E. S. (2022). Recognizing Indigenous peoples' and local communities' rights and agency in the post-2020 Biodiversity Agenda. Ambio, 51(1), 84–92. https://doi.org/10.1007/s13280-021-01561-7
41. Salehi, B., Sharifi-Rad, J., Cappellini, F., Reiner, Ž., Zorzan, D., Imran, M., Sener, B., Kilic, M., El-Shazly, M., & Fahmy, N. M. (2020). The therapeutic potential of anthocyanins: Current approaches based on their molecular mechanism of action. Frontiers in Pharmacology, 11, 567172.
42. Samuels, N., Ben-Arye, E., Maimon, Y., & Berger, R. (2017). Unmonitored use of herbal medicine by patients with breast cancer: Reframing expectations. Journal of Cancer Research and Clinical Oncology, 143(11), 2267–2273. https://doi.org/10.1007/s00432-017-2471-x
43. Seethapathy, G. S., Raclariu-Manolica, A.-C., Anmarkrud, J. A., Wangensteen, H., & de Boer, H. J. (2019). DNA metabarcoding authentication of ayurvedic herbal products on the European market raises concerns of quality and fidelity. Frontiers in Plant Science, 10, 68.
44. Sharifi-Rad, J., Rayess, Y. E., Rizk, A. A., Sadaka, C., Zgheib, R., Zam, W., Sestito, S., Rapposelli, S., Neffe-Skocińska, K., & Zielińska, D. (2020). Turmeric and its major compound curcumin on health: Bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Frontiers in Pharmacology, 11, 550909.
45. Sorokina, M., Merseburger, P., Rajan, K., Yirik, M. A., & Steinbeck, C. (2021). COCONUT online: Collection of Open Natural Products database. Journal of Cheminformatics, 13(1), 2. https://doi.org/10.1186/s13321-020-00478-9
46. Sorokina, M., & Steinbeck, C. (2020). Review on natural products databases: Where to find data in 2020. Journal of Cheminformatics, 12(1), 20. https://doi.org/10.1186/s13321-020-00424-9
47. Suroowan, S., Pynee, K. B., & Mahomoodally, M. F. (2019). A comprehensive review of ethnopharmacologically important medicinal plant species from Mauritius. South African Journal of Botany, 122, 189–213.
48. Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018). Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. International Journal of Molecular Sciences, 19(6), 1578.
49. Upton, R., David, B., Gafner, S., & Glasl, S. (2020). Botanical ingredient identification and quality assessment: Strengths and limitations of analytical techniques. Phytochemistry Reviews, 19(5), 1157–1177. https://doi.org/10.1007/s11101-019-09625-z
50. Uzun, S. P., & Koca, C. (2020). Ethnobotanical survey of medicinal plants traded in herbal markets of Kahramanmaraş. Plant Diversity, 42(6), 443–454.
51. Vandebroek, I., Pieroni, A., Stepp, J. R., Hanazaki, N., Ladio, A., Alves, R. R. N., Picking, D., Delgoda, R., Maroyi, A., & Van Andel, T. (2020). Reshaping the future of ethnobiology research after the COVID-19 pandemic. Nature Plants, 6(7), 723–730.
52. Weckerle, C. S., De Boer, H. J., Puri, R. K., Van Andel, T., Bussmann, R. W., & Leonti, M. (2018). Recommended standards for conducting and reporting ethnopharmacological field studies. Journal of Ethnopharmacology, 210, 125–132.
53. Wolfender, J.-L., Litaudon, M., Touboul, D., & Queiroz, E. F. (2019). Innovative omics-based approaches for prioritisation and targeted isolation of natural products–new strategies for drug discovery. Natural Product Reports, 36(6), 855–868.
54. Xu, H.-Y., Zhang, Y.-Q., Liu, Z.-M., Chen, T., Lv, C.-Y., Tang, S.-H., Zhang, X.-B., Zhang, W., Li, Z.-Y., & Zhou, R.-R. (2019). ETCM: An encyclopaedia of traditional Chinese medicine. Nucleic Acids Research, 47(D1), D976–D982.

55. Zhang, R., Zhu, X., Bai, H., & Ning, K. (2019). Network pharmacology databases for traditional Chinese medicine: Review and assessment. Frontiers in Pharmacology, 10, 123.
56. Zhou, H., Zhang, J., Kirbis, B. S., Mula, Z., Zhang, W., Kuang, Y., Huang, Q., & Yin, L. (2023). Ethnobotanical study on medicinal plants used by Bulang people in Yunnan, China. Journal of Ethnobiology and Ethnomedicine, 19(1), 38. https://doi.org/10.1186/s13002-023-00609-0